Home/ Stocks/ ANVS

Annovis Bio, Inc.

ANVS XNYS

$1.88 +0.02 (+1.08%) ▲ 15-min delayed

Open

$1.90

High

$1.95

Low

$1.85

Volume

557.2K

Market Cap

$79.13M

About Annovis Bio, Inc.

Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 7 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-17,606,382	$-0.63
FY 2025	$0	$-28,854,197	$-1.40
Q3 2025	$0	$-7,262,658	$-0.37
Q2 2025	$0	$-6,220,058	$-0.32

Related Market News

No specific coverage for ANVS yet. Check out our latest market news or earnings calendar.

Get ANVS Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Annovis Bio, Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.